Amneal Pharmaceuticals, Inc. (AMRX) Stock

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, New Jersey, is a leading developer, licensor, manufacturer, marketer, and distributor of both generic and specialty pharmaceutical products worldwide. The company operates through three distinct segments: Generics, Specialty, and AvKARE, each catering to specific therapeutic areas and market needs.

In the Generics segment, Amneal specializes in the development and commercialization of a wide array of pharmaceutical formulations including oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals. These products span various therapeutic categories, addressing critical healthcare needs across global markets.

The Specialty segment focuses on branded pharmaceuticals, with an emphasis on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. Notable products include Emverm for intestinal parasite treatment, Rytary for Parkinson's disease, and Unithroid for hypothyroidism, highlighting Amneal's commitment to innovation in specialty pharmaceuticals.

Amneal's AvKARE segment specializes in providing pharmaceuticals, medical and surgical products, and services primarily to governmental agencies such as the Department of Defense and the Department of Veterans Affairs. This segment also engages in wholesale distribution of pharmaceuticals under the AvKARE and AvPAK brands, serving both retail and institutional customers.

Founded in 2002 as Atlas Holdings, Inc., and rebranded as Amneal Pharmaceuticals, Inc. in 2018, the company has expanded its operations globally, with a strong presence in the United States, India, Ireland, and beyond. Amneal Pharmaceuticals continues to drive innovation in pharmaceutical development and distribution, aiming to enhance healthcare accessibility and improve patient outcomes worldwide.